The top hit compounds were also tested on the other edited prostate cancer cell line, DU145-HiBiT (Figure S3A,B), and on parental non-edited DU145 cells (Figure S3C), confirming their action on DAB2IP. Here, DAB2IP is linked to prostate carcinoma.